NRXPNasdaqPharmaceutical PreparationsFiscal year ends December 31
NRX Pharmaceuticals, Inc.
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 14, 2026
$2.63+0.03 (+1.15%)
Close on Oct 19, 2026
- Market cap
- $99.02M
- P/E (TTM)
- –
- Dividend yield
- –
NRX Pharmaceuticals, Inc. revenue by segment
By business segment
| Operating income | TTM Q2 26 | TTM Q4 25 |
|---|---|---|
| Dura Segment [Member] | $95.00K | -$87.00K |
| NRx Segment [Member] | -$19.99M | -$16.14M |
By product or service
| Revenue | TTM Q2 26 | TTM Q4 25 | % of revenue |
|---|---|---|---|
| Therapy [Member] | $2.49M | $854.00K | 73.2% |
| Procedures [Member] | $909.00K | $371.00K | 26.8% |
By region
From the segment and revenue-disaggregation notes of NRX Pharmaceuticals's 10-K and 10-Q filings (XBRL). Fourth-quarter figures are the fiscal year less the first nine months. Segment names follow the company's own labels and can change when it reorganizes.